IPIX Milestones, Clinical Trials, Recent Articles,

IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patents

Q3 Potential Milestones

1. B-OM - Breakthrough Therapy Designation
2. Prurisol - Top-line Data (Phase 2b)
3. Licensing Agreement (double-digits millions upfront payment)

http://www.ipharminc.com/press-release/2018/6...re-capital

Past Milestones



Kevetrin

- Positive primary endpoint (Phase 2a)
http://www.ipharminc.com/press-release/2018/2...3-observed

- Highly encouraging preliminary data (Phase 2a)
http://www.ipharminc.com/press-release/2017/1...ncer-trial

- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/1...e-patients

- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/1...ian-cancer

- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/1...tic-cancer

- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma

- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma

Brilacidin

- B-OM positive secondary endpoint (Phase 2)
http://www.ipharminc.com/press-release/2018/1...ositis-som

- B-OM positive top-line data (Phase 2)
http://www.ipharminc.com/press-release/2017/1...r-patients

- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7...brilacidin

- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/1...daptomycin

- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/1...n-from-fda

- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/1...-mucositis

- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/1...infections

- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/1...oot-ulcers

- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1

Prurisol

- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/1...y-endpoint

- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/1...ical-trial

- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/1...iasis-drug

Clinical Trials

1. K-OC (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT030427...amp;rank=1

2. P (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2

3. B-OM (Phase 2, Completed )
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

4. P (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=4

5. P (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT029493...amp;rank=5

6. B-ABSSSI (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=6

7. K (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=7

8. B-UP (Phase 2 POC, Completed )
http://www.ipharminc.com/press-release/2016/1...-proctitis

Pipeline



Recent Articles

- Taking a Page from Merck’s Gardasil and Glaxo’s Requip, These Small Companies Look to Cement Riches for Shareholders in New Category of Oral Mucositis
http://www.baystreet.ca/articles/stockstowatc...-Mucositis

- A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug: Five Companies That Want It
http://www.baystreet.ca/stockstowatch/2658/A-...at-Want-It

- Innovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year End
https://seekingalpha.com/article/4088788-inno...n-year-end

- 2017 Q3 Conference Call Transcript
https://seekingalpha.com/article/4080068-inno...transcript

- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellc...transcript

- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino

- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone

- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen

Corporate Overview

- April 2018
https://static1.squarespace.com/static/571535...erview.pdf

- 2018 Biotech Showcase
https://static1.squarespace.com/static/571535...erview.pdf

- BioCentury NewsMakers Conference
https://static1.squarespace.com/static/571535...ep2017.pdf

- Drug Discovery and Therapy World Congress
https://static1.squarespace.com/static/571535...ul2017.pdf

Patents

- Kevetrin
https://www.google.com/patents/US8338454

- Brilacidin
https://www.sec.gov/Archives/edgar/data/13552...ex1037.htm
https://www.google.com/patents/US20160243117
https://www.google.com/patents/EP2709619A2

- Prurisol
https://www.google.com/patents/WO2013103601A1

MP Advisors Report

https://drive.google.com/file/d/0Bz15O4eaX-as...hENFk/view

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product